<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4184366</article-id><article-id pub-id-type="publisher-id">1546-0096-12-S1-P96</article-id><article-id pub-id-type="doi">10.1186/1546-0096-12-S1-P96</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Safety and efficacy of creatine supplementation in juvenile dermatomyositis: a randomized double-blind placebo-controlled cross-over trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Sallum</surname><given-names>Adriana</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Solis</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Hayashi</surname><given-names>Ana Paula</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Artioli</surname><given-names>Guilherme</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Sapienza</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Otaduy</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Pinto</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Silva</surname><given-names>Cl&#x000f3;vis</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Pereira</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Gualano</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>School of Medicine, University of S&#x000e3;o Paulo, S&#x000e3;o Paulo, Brazil</aff><aff id="I2"><label>2</label>School of Physical Education and Sport , University of S&#x000e3;o Paulo, S&#x000e3;o Paulo, Brazil</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2014</year></pub-date><volume>12</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the 21st European Pediatric Rheumatology (PReS) Congress</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by the PReS 2014 congress.</named-content></supplement><fpage>P96</fpage><lpage>P96</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Sallum et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Sallum et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/12/S1/P96"/><conference><conf-date>17-21 September 2014</conf-date><conf-name>21st European Pediatric Rheumatology (PReS) Congress</conf-name><conf-loc>Belgrade, Serbia</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Juvenile dermatomyositis patients may experience persistent weakness, loss of bone mass, and skeletal muscle atrophy as a long-term result of drug treatment and/or disease itself. In this regard, efforts to develop new therapeutic strategies able to attenuate these adverse outcomes have been considered of clinical relevance. It has been suggested that creatine supplementation could be safe, effective and inexpensive for treating idiopathic inflammatory myopathies, but no pediatric study has been conducted so far.</p></sec><sec><title>Objectives</title><p>To examine the safety and efficacy of creatine supplementation in JDM patients</p></sec><sec sec-type="methods"><title>Methods</title><p>JDM patients received placebo or creatine supplementation (0.1 g/kg/d) in a randomized, crossover, double-blind, repeated-measures design. Subjects were assessed at baseline and after 12 weeks, with 8-week washout period. Primary outcome was muscle function. Secondary outcomes included body composition, bone mineral density, biochemical markers of bone remodeling, inflammatory cytokines, aerobic conditioning, health-related quality of life, and disease-related parameters, dietary intake and muscle phosphorylcreatine (PCR) content. Safety was assessed by laboratory parameters and kidney function</p></sec><sec sec-type="results"><title>Results</title><p>Intramuscular PCR content was not significantly different between creatine and placebo before or after the intervention (Creatine - Pre: 21.4 &#x000b1; 5.3, Post: 20.6 &#x000b1; 2.7, delta score = -0.3 &#x000b1; 2.5 mmol/kg wet muscle, ES = -0.15; Placebo - Pre: 20.4 &#x000b1; 3.7, Post: 20.7 &#x000b1; 3.6, delta score = -0.1 &#x000b1; 4.2 mmol/kg wet muscle, ES = -0.15; 95% CI for delta score = -2.8 &#x000b1; 2.4, p = 0.45 for interaction between creatine and placebo). No significant changes between placebo and creatine for muscle function and aerobic conditioning, body composition, bone mineral density, and quality of life were seen, probably due to the lack of change in intramuscular PCR content. Kidney function was not changed after creatine supplementation and no side effects were noticed.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>A 12-week creatine supplementation protocol is well tolerable and free of adverse effects but did not affect intramuscular PCR, muscle function, body composition, bone mineral density or quality of life in JDM patients.</p></sec><sec><title>Disclosure of interest</title><p>None declared.</p></sec></body></article>